Q1 Earnings Forecast for SABS Issued By Leerink Partnrs

SAB Biotherapeutics, Inc. (NASDAQ:SABS) – Research analysts at Leerink Partnrs issued their Q1 2026 earnings estimates for SAB Biotherapeutics in a research report issued on Sunday, November 23rd. Leerink Partnrs analyst T. Smith expects that the company will post earnings per share of ($0.12) for the quarter. Leerink Partnrs currently has a “Strong-Buy” rating on the stock. The consensus estimate for SAB Biotherapeutics’ current full-year earnings is ($3.69) per share. Leerink Partnrs also issued estimates for SAB Biotherapeutics’ Q2 2026 earnings at ($0.10) EPS, Q3 2026 earnings at ($0.08) EPS, Q4 2026 earnings at ($0.10) EPS and FY2029 earnings at $0.18 EPS.

SAB Biotherapeutics (NASDAQ:SABS) last released its earnings results on Friday, November 14th. The company reported ($0.21) EPS for the quarter, beating the consensus estimate of ($0.59) by $0.38.

SABS has been the subject of several other research reports. Leerink Partners began coverage on shares of SAB Biotherapeutics in a research note on Wednesday, September 17th. They issued an “outperform” rating and a $7.00 target price for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of SAB Biotherapeutics in a research report on Monday, November 17th. Wall Street Zen raised SAB Biotherapeutics from a “sell” rating to a “hold” rating in a report on Saturday. Finally, Chardan Capital restated a “buy” rating and issued a $12.00 target price on shares of SAB Biotherapeutics in a research note on Monday, November 17th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, SAB Biotherapeutics currently has an average rating of “Moderate Buy” and an average target price of $9.33.

SAB Biotherapeutics Stock Performance

NASDAQ:SABS opened at $3.93 on Tuesday. The firm’s 50-day moving average is $2.83 and its 200-day moving average is $2.34. SAB Biotherapeutics has a 52-week low of $1.00 and a 52-week high of $6.60. The company has a debt-to-equity ratio of 0.02, a quick ratio of 10.50 and a current ratio of 10.49. The company has a market cap of $187.11 million, a price-to-earnings ratio of -1.27 and a beta of 0.60.

Institutional Trading of SAB Biotherapeutics

Several institutional investors have recently bought and sold shares of the stock. ADAR1 Capital Management LLC bought a new stake in SAB Biotherapeutics in the third quarter valued at $30,000. Dimensional Fund Advisors LP acquired a new stake in shares of SAB Biotherapeutics in the 3rd quarter valued at $32,000. Virtu Financial LLC acquired a new stake in shares of SAB Biotherapeutics in the 3rd quarter valued at $40,000. HB Wealth Management LLC grew its holdings in shares of SAB Biotherapeutics by 10.9% in the 1st quarter. HB Wealth Management LLC now owns 263,200 shares of the company’s stock worth $358,000 after purchasing an additional 25,800 shares during the last quarter. Finally, Woodline Partners LP acquired a new stake in shares of SAB Biotherapeutics during the 3rd quarter worth about $5,730,000. Institutional investors and hedge funds own 7.82% of the company’s stock.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.